Fulltext

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Muro K 1 , Lordick F 2 , Tsushima T 3 , Pentheroudakis G 4 , Baba E 5 , Lu Z 6 Show all authors , Cho BC 7 , Nor IM 8 , Ng M 9 , Chen LT 10 , Kato K 11 , Li J 12 , Ryu MH 13 , Zamaniah WIW 14 , Yong WP 15 , Yeh KH 16 , Nakajima TE 17 , Shitara K 18 , Kawakami H 19 , Narita Y 20 , Yoshino T 18 , Van Cutsem E 21 , Martinelli E 22 , Smyth EC 23 , Arnold D 24 , Minami H 25 , Tabernero J 26 , Douillard JY 27

Affiliations 

  • 1 Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. Electronic address: kmuro@aichi-cc.jp
  • 2 University Cancer Center Leipzig, Leipzig; 1st Department of Medicine (Hematology and Medical Oncology), University Hospital Leipzig, Leipzig, Germany
  • 3 Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
  • 4 Department of Medical Oncology, University of Ioannina, Ioannina, Greece
  • 5 Department of Comprehensive Clinical Oncology, Kyushu University, Fukuoka, Japan
  • 6 Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
  • 7 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
  • 8 Department of Radiotherapy & Oncology, General Hospital, Kuala Lumpur, Malaysia
  • 9 Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  • 10 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
  • 11 Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
  • 12 Department of Oncology, Tongji University affiliated East Hospital, Shanghai, China
  • 13 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
  • 14 Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 15 Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
  • 16 Department of Oncology, National Taiwan University Hospital, Taipei; National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan
  • 17 Department of Clinical Oncology, School of Medicine, St. Marianna University, Kawasaki
  • 18 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa
  • 19 Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan
  • 20 Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
  • 21 Digestive Oncology, University Hospitals Leuven, Leuven, Belgium
  • 22 Department of Experimental Medicine - Medical Oncology, Università degli Studi della Campania L Vanvitelli, Napoli, Italy
  • 23 Department of Oncology, University of Cambridge, Cambridge, UK
  • 24 Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany
  • 25 Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
  • 26 Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain
  • 27 ESMO, Lugano, Switzerland
Ann Oncol, 2019 Jan 01;30(1):34-43.
PMID: 30475943 DOI: 10.1093/annonc/mdy498

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications